Medical News

RSS

Blind mole-rats live underground in low-oxygen environments, are long-lived and resistant to cancer

Like naked mole-rats (Heterocephalus gaber), blind mole-rats (of the genus Spalax) live underground in low-oxygen environments, are long-lived and resistant to cancer. A new study demonstrates just how cancer-resistant Spalax are, and suggests that the adaptations that help these rodents survive in low-oxygen environments also play a role in their longevity and cancer resistance.

4 Sep 2013

Study: Changes in expression of various isoforms might play role in cancer development

Spool-like proteins called histones play a crucial role in packaging the nearly seven feet of DNA found in most human cells. A new study shows that a group of histones that are thought to behave the same way actually are functionally distinct proteins.

4 Sep 2013

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

4 Sep 2013

More young people show risk factors for common type of strokes

Fifteen percent of the most common type of strokes occur in adolescents and young adults, and more young people are showing risk factors for such strokes, according to a report in the journal Neurology.

4 Sep 2013

Avanir Pharmaceuticals enters into patent settlement agreement with Actavis

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Actavis South Atlantic LLC and Actavis, Inc. (collectively, "Actavis") to resolve pending patent litigation in response to Actavis' abbreviated new drug application seeking approval to market generic versions of Avanir's NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) capsules.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Inhaled steroids linked to improved school performance in asthma

Researchers from Greece say that the use of steroid inhalers in elementary school children with asthma may improve school performance over other forms of therapy.

3 Sep 2013

Genetic score backs schizophrenia spectrum

Researchers report that polygenic scores derived from one well-characterized cohort of schizophrenia patients correspond to clinical diagnostic categories in another.

3 Sep 2013

Bipolar patients struggle with emotional distraction

Patients with bipolar disorder struggle with cognitive tasks in the face of emotional distractions, a study shows.

3 Sep 2013

Cangene Signs Up To $77M Contract Extension With CDC

...

3 Sep 2013

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

...

3 Sep 2013

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

...

3 Sep 2013

Cangene Inks Up To $77M Contract Extension With CDC

...

3 Sep 2013

Chronic granulomatous disease (CGD) research: an interview with Dr. Griffin Rodgers, NIDDK director

Chronic granulomatous disease, or CGD, is a diverse group of inherited diseases in which certain cells of the immune system have difficulty forming reactive oxygen compounds, most importantly superoxide radicals. These are used by these white blood cells to kill certain bacteria.

3 Sep 2013

Implantation rate of CIEDs continues to rise in most European countries

Infections cause a lower proportion of lead extractions than expected, according to preliminary results from the ELECTRa Registry presented at ESC Congress 2013 today by Dr Maria Grazia Bongiorni from Italy.

3 Sep 2013

VolitionRx-led consortium receives grant to develop novel NuQ biomarkers for immune response

...

3 Sep 2013

Viralytics releases financial results for 2013

Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013.

3 Sep 2013

BME introduces new, improved Speed Continuous Active Compression System

BME, Inc., the privately held U.S. Leader in Nitinol Technology Implants and Instruments known under the brands of: Speed™ (fully-disposable continuous active compression system), HammerLock® (intramedullary hammertoe correction system), OSStaple™ (Nitinol continuous active compression system) and OSSforce™ (heat-activating implant controller), has announced today its' introduction of a new, improved Speed™ Continuous Active Compression System.

3 Sep 2013

Sanomedics completes acquisition of Prime Time Medical

Sanomedics International Holdings, Inc., a medical technology holding company that focuses on game-changing products, services and ideas, today announced that it has completed the previously announced acquisition of Prime Time Medical, Inc., of Largo, Florida for a total purchase price of $3,100,000, effective August 30, 2013.

3 Sep 2013

Sigma Life Science signs license agreement with Horizon Discovery for CompoZr ZFN technology

Sigma-Aldrich Corporation today announced that Sigma Life Science, its innovative biological products and services business, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma's CompoZr Zinc Finger Nuclease technology.

3 Sep 2013